{"organizations": [], "uuid": "fb1d548b2915a432ec0b20ea30964195d6fd82b9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vertex-initiates-phase-3-studies-o/brief-vertex-initiates-phase-3-studies-of-vx-445-tezacaftor-and-ivacaftor-idUSFWN1S31SB", "country": "US", "domain_rank": 408, "title": "Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.578, "site_type": "news", "published": "2018-04-27T04:40:00.000+03:00", "replies_count": 0, "uuid": "fb1d548b2915a432ec0b20ea30964195d6fd82b9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vertex-initiates-phase-3-studies-o/brief-vertex-initiates-phase-3-studies-of-vx-445-tezacaftor-and-ivacaftor-idUSFWN1S31SB", "ord_in_thread": 0, "title": "Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vertex", "sentiment": "negative"}, {"name": "vertex pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "vertex pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS\n* VERTEX PHARMACEUTICALS - FIRST PHASE 3 STUDY WILL EVALUATE ABOUT 360 PEOPLE WITH CF WHO HAVE 1 COPY OF F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION\n* VERTEX PHARMACEUTICALS INC - SECOND PHASE 3 STUDY WILL EVALUATE APPROXIMATELY 100 PEOPLE WITH CF WHO HAVE TWO COPIES OF F508DEL MUTATION\n* VERTEX - ANNOUNCES RESULTS FOR VX-561 WHEN DOSED AS PART OF A TRIPLE COMBO REGIMEN IN PHASE 2 STUDIES OF PEOPLE WITH 1 F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION\n* VERTEX PHARMACEUTICALS INC - VX-561 WHEN DOESED AS PART OF THE TRIPLE COMBINATION REGIMENS WERE GENERALLY WELL TOLERATED Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T04:40:00.000+03:00", "crawled": "2018-04-27T16:49:14.004+03:00", "highlightTitle": ""}